Princeton Alpha Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Princeton Alpha Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-2,562	Closed	-$206K	–	701
2015 Q3	$206K	Buy	2,562 +3	+0.1%	+$333	0.04%	602
2015 Q2	$307K	Buy	+2,559	New	+$306K	0.06%	446

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Princeton Alpha Management's ALNY Position: Q4 2015 in Review

Princeton Alpha Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2015, closing a stake of 2,562 shares — an estimated $206K sold.

Princeton Alpha Management first reported a position in ALNY in Q2 2015 and held it in 2 quarters. The position peaked at $307K in Q2 2015. 261 funds tracked by Wall St. Rank hold ALNY as of Q4 2015.

Princeton Alpha Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
Princeton Alpha Management sold 2,562 Alnylam Pharmaceuticals shares in Q4 2015, an estimated $206K.
Princeton Alpha Management first reported a position in Alnylam Pharmaceuticals in Q2 2015 and held it in 2 quarters.
Princeton Alpha Management's Alnylam Pharmaceuticals position peaked at $307K in Q2 2015.
261 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2015.

Based on Princeton Alpha Management's 13F filing for Q4 2015, filed 4 Feb 2016.